Recommendations from the EGAPP Working Group: Routine testing for Factor V Leiden (R506Q) and prothrombin (20210G>A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members

Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group*

Summary of Recommendations: The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group found adequate evidence to recommend against routine testing for Factor V Leiden (FVL) and/or prothrombin 20210G>A (PT) in the following circumstances: (1) adults with idiopathic venous thromboembolism (VTE). In such cases, longer term secondary prophylaxis to avoid recurrence offers similar benefits to patients with and without one or more of these mutations. (2) Asymptomatic adult family members of patients with VTE and an FVL or PT mutation, for the purpose of considering primary prophylactic anticoagulation. Potential benefits are unlikely to exceed potential harms. The overall certainty of these findings was deemed “moderate.” The evidence was insufficient to determine whether FVL/PT testing might have clinical utility in some circumstances, such as for identifying FVL homozygosity among asymptomatic family members of adults with idiopathic VTE or counseling patients about the risks and benefits of antithrombotic therapy. Based on the available evidence, the certainty of net health benefit was deemed “low.” The recommendations do not extend to patients with other risk factors for thrombosis, such as contraceptive use, as the evidence review that serves as the basis for the recommendations focused primarily on idiopathic VTE.

Rationale: In developing these recommendations the EGAPP Working Group considered evidence in the following three areas. Analytic Validity: There is adequate evidence that testing accurately and reliably detects the R506Q (FVL) and 20210G>A (PT) variants in the Factor V and PT genes, respectively (a more complete definition of analytic validity, clinical validity, and clinical utility is contained under the “Clinical Considerations” section). Clinical Validity: The presence of a heterozygous FVL variant seems to be a weak risk factor for recurrence of VTE (odds ratio [OR]: 1.56). Rare homozygous FVL mutations present somewhat greater risks of VTE recurrence (OR: 2.65). The evidence for this increased risk is convincing, but the magnitude of excess risk is not as great as previously thought. The evidence is insufficient to draw conclusions about excess VTE recurrence risk resulting from compound heterozygosity (FVL and PT), but it is likely to be at least as high as with FVL alone. The OR for compound heterozygosity is 6.69. The evidence is insufficient to draw conclusions about VTE recurrence risks associated with PT mutations alone. For family members of index VTE cases, there is convincing evidence that both heterozygosity and homozygosity for FVL are associated with higher risks for VTE occurrence (ORs 3.49 and 17.84, respectively) than for family members without FVL variants. Clinical Utility: There is convincing evidence that longer term secondary prophylaxis after an initial idiopathic VTE event yields comparable benefits to those with and without a FVL or PT mutation. For asymptomatic family members of index cases, no prophylaxis trials have been reported. Hence, there is no direct evidence of particular benefit to family members. Potential net harm is possible if primary prophylaxis is administered to asymptomatic family members with one or more mutations, because the absolute risk of an initial VTE event is low, and the risk of anticoagulant-induced hemorrhage is relatively high. Genet Med 2011:13(1): 67–76.

Key Words: Factor V Leiden, prothrombin, venous thromboembolism

*EGAPP Working Group: Chair: Alfred O. Berg, MD, MPH (Department of Family Medicine, University of Washington); Members: Jeffrey Botkin, MD, MPH (University of Utah); Ned Calonge, MD, MPH (Colorado Department of Public Health and Environment); Doug Campos-Outcalt, MD, MPA (Department of Family-Community Medicine, University of Arizona College of Medicine, Phoenix); James E. Haddow, MD (Department of Pathology and Laboratory Medicine, The Warren Alpert Medical School of Brown University); Maxine Hayes, MD, MPH (Washington State Department of Health); Celia Kaye, MD, PhD (Department of Pediatrics, University of Colorado School of Medicine); Roger D. Klein, MD, JD (Blood Center of Wisconsin; Medical College of Wisconsin); Kenneth Offit, MD, MPH (Clinical Genetics Service, Memorial Sloan-Kettering Cancer Center); Stephen G. Pauker, MD, MACP, FACC, ABMH (Division of Clinical Decision Making, Informatics and Telemedicine, Department of Medicine, Tufts Medical Center); Margaret Piper, PhD, MPH (Blue Cross/Blue Shield Association Technology Evaluation Center); Carolyn Sue Richards, PhD, FACMG (Oregon Health & Science University); Joan A. Scott, MS, CGC (Genetics and Public Policy Center, Johns Hopkins University); Ora L. Strickland, PhD, DSc (Hon.), RN, FAAN (Nell Hodgson Woodruff School of Nursing, Emory University); Steven Teutsch, MD, MPH (Los Angeles County Department of Public Health); David L. Veenstra, PharmD, PhD (Pharmaceutical Outcomes Research and Policy Program, and Institute for Public Health Genetics, University of Washington).
Definitions used by evaluation of genomic applications in practice and prevention

- Factor V Leiden (FVL; R506Q), the most common known inherited risk factor for thrombosis, results from a base change from G to A at position 1691 of the gene encoding coagulation Factor V. The associated amino acid substitution eliminates one of three activated Protein C cleavage sites in the Factor V protein, resulting in Factor V being inactivated more slowly and generating more thrombin, thereby enhancing the potential for clot formation.
- Prothrombin (PT; 20210G>A), the second most common known inherited risk factor for thrombosis, is a gene variant that produces an amino acid substitution in the PT protein, which results in higher circulating PT levels and an enhanced potential for clot formation.
- Venous thromboembolism (VTE), including deep venous thrombosis and pulmonary embolism, is characterized by pathologic thrombosis occurring in the venous circulatory system.1–3 The present report deals with idiopathic VTE (also referred to as “unprovoked” VTE), meaning that the event occurs in the absence of a known precipitating factor, such as oral contraceptives, surgery, trauma, or cancer.
- Thrombophilia refers to an acquired or inherited condition that predisposes to the development of pathologic thromboses.
- Analytic validity refers to the ability of a test to accurately and reliably measure the genotype or analyte of interest, in this case the above-described mutations in Factor V and PT genes.
- Clinical validity is defined as a test’s ability to accurately and reliably identify or predict the disorder or phenotype of interest, in this case the ability of FVL and PT mutation testing to predict occurrence or recurrence of VTE.
- Clinical utility defines the balance of benefits and harms associated with the use of the test in practice, including improvement in measurable clinical outcomes and usefulness/added value in clinical management and decision making, compared with not using the test. In the present context, clinical utility depends on the extent to which identification of a FVL or PT mutation alters management in index cases with VTE and leads to health-related outcomes that are significantly improved over current practice. Among family members of index cases, clinical utility again depends on the extent to which management changes when a mutation is identified and most importantly how effectively such management leads to avoidance of VTE. A test may be found to have clinical validity (i.e., be a legitimate risk factor for the disorder) without having clinical utility if there is not sufficient evidence to show benefits resulting from use of the test. In the present context, clinical utility of FVL and PT will depend on whether their identification affects patient management and outcome.

Patient population under consideration

These recommendations apply to adults with a history of idiopathic VTE and their asymptomatic adult family members. The recommendations do not extend to individuals with other known risk factors for thrombosis, such as contraceptive use.
changes, and swelling. The cumulative incidence of this syndrome is 22.8% after 2 years, 28% after 5 years, and 29.1% after 8 years.16 In patients with a first episode of proximal deep venous thrombosis, the cumulative incidence of mild-to-moderate postthrombotic syndrome is approximately 50% and of severe postthrombotic syndrome 23%.13 The postthrombotic syndrome is more likely to occur after recurrent episodes of deep venous thrombosis and can have great impact on quality of life, with leg ulcers being one of the most serious complications. After a first episode of venous thrombosis, elastic stockings reduce the risk of developing postthrombotic syndrome by 50%.13

FVL and PT frequency

In the United States, approximately 5.1%, 2.0%, and 1.2% of the non-Hispanic white, Hispanic white, and African American populations are heterozygous for the FVL mutation, respectively. Corresponding rates of homozygosity are much lower (65, 10, and 4 per 100,000 individuals, respectively).17–19 An FVL mutation is present in 15–20% of individuals with an initial episode of VTE, making it the most common known heritable thrombophilic risk factor.20 Population studies have suggested that a single FVL variant (homozygosity) increases risk for an initial episode of VTE by 4- to 7-fold over the annual background risk of less than one per thousand, whereas two copies (homozygosity) increase that risk by 9- to 80-fold.18–21 A recent retrospective study, involving subjects who were first-degree relatives of patients who had experienced DVT, PE, or arterial thrombosis before reaching the age of 50 years, found the annual incidence of DVT to be 0.41% (95% confidence interval [CI], 0.28–0.58) among carriers and 0.19% (95% CI, 0.16–0.23) among noncarriers of FVL, for a relative risk of 2.1 (95% CI, 1.4–3.2). When inheritance of additional known thrombophilic mutations was excluded from the analysis, relative risk for DVT increased to 7.0 (95% CI, 2.3–21.7) among FVL carriers.22

The PT mutation is the second most common heritable risk factor for VTE. In the United States, approximately 2.2%, 2.2%, and 0.6% of non-Hispanic white, Hispanic white, and African American populations, respectively, are heterozygous for the PT mutation.17 Individuals homozygous for this mutation are rare (12, 12, and <1 per 100,000 individuals, respectively). The PT mutation is present in 6% of individuals with an initial episode of venous thrombosis and seems to increase risk for VTE by 2- to 4-fold.19,23 In the general population, individuals with both an FVL mutation and PT mutation (compound heterozygotes) occur at the rate of 22 per 100,000. In such individuals, there is an estimated 20-fold increased risk for an initial episode of VTE.19,20,24 Among patients with VTE who are heterozygous for FVL, 12% will also be heterozygous for PT.19,20,24 There is some evidence that the prevalence of the FVL mutation is higher in patients with uncomplicated deep venous thrombosis (i.e., without pulmonary embolism) than in patients with pulmonary embolism (with or without deep venous thrombosis).23,24 By contrast, the frequency of the PT mutation among individuals with uncomplicated deep venous thrombosis is not different from those with pulmonary embolism.19,24

Clinical context

Evaluation of Genomic Applications in Practice and Prevention (EGAPP) commissioned an evidence-based review to address an overarching question regarding the following specific clinical scenario: “Does FVL mutation testing, alone or in combination with PT mutation testing, lead to improved clinical outcomes (e.g., avoidance of recurrent VTE) in adults with a personal history of VTE or to improved outcomes (e.g., avoidance of an initial VTE) in adult family members of mutation-positive individuals? Are the testing results useful in medical, personal, or public health decision-making?”2 The present recommendation relies on evidence from that review, which was aimed at documenting the extent to which FVL and PT testing leads to improved health outcomes for individuals with VTE and one or more of these thrombophilic risk factors (by individualized treatment) and for members of these individuals’ families (by management strategies to minimize both initial and recurrent thrombotic events).

REVIEW OF SCIENTIFIC EVIDENCE

This statement summarizes the supporting scientific evidence used by the EGAPP Working Group (EWG) to make recommendations regarding the use of FVL and PT mutation testing in adults with a personal history of VTE and in asymptomatic adult family members of mutation-positive individuals.

Methods

EGAPP is a project developed by the Office of Public Health Genomics at the Centers for Disease Control and Prevention to support a rigorous, evidence-based process for evaluating genetic tests and other genomic applications being proposed (or used in) clinical and public health practice in the United States. A key goal of the EWG is to develop conclusions and recommendations regarding clinical genomic applications and to establish clear linkage to the supporting scientific evidence. The EWG members are nonfederal multidisciplinary experts convened to establish methods and processes, set priorities for review topics, participate in technical expert panels for commissioned evidence review topics, and develop and publish recommendations.

EGAPP commissioned an evidence review through the Agency for Health care Research and Quality, and this review was conducted by investigators at The Johns Hopkins University Evidence-Based Practice Center. The final report “Outcomes of Genetic Testing in Adults with a History of Venous Thromboembolism” is available online. Peer-reviewed summary reports of the evidence for analytic validity and clinical validity have also been published. Because it was anticipated that data might not be available to directly answer the overarching question, the EWG constructed an analytic framework and key questions to address different components of evaluation (e.g., analytic validity, clinical validity, and clinical utility) for the purpose of providing relevant indirect evidence of efficacy. Established Agency for Healthcare Research and Quality Evidence-based Practice Center methods were followed in conducting this review. A Technical Expert Panel that included three EWG members provided expert guidance during the course of the review. EWG members reviewed the evidence report, key primary publications, other sources of information, and comments on the evidence report from the test developers. The process also included assessment of key gaps in knowledge and relevant contextual factors (e.g., availability of diagnostic or therapeutic alternatives, feasibility and practicality of implementation, and cost-effectiveness). The final EWG recommendation statement was formulated based on magnitude of effect, certainty of evidence, and consideration of contextual factors.
Technology

Methods currently in use can be determined from the 2009 College of American Pathologists (CAP) Proficiency Testing Survey that included 335 laboratories that tested for FVL (325 of these also performed PT testing). Most laboratories use a polymerase chain reaction method or the Invader technology. Smaller numbers use allele-specific polymerase chain reaction/amplification refractory mutation system, microarray technologies, bead arrays, oligoligation assays, pyrosequencing, and other methods. Many of these laboratory methodologies are described in the American College of Medical Genetics Standards and Guidelines for Clinical Genetic Laboratories (http://www.acmg.net/Pages/ACMG_Activities/stds-2002/g.htm).

Analytic validity

In the current clinical scenario, analytic validity is defined as a laboratory’s ability to accurately and reliably detect the FVL mutation (R506Q) and a single PT mutation (20210 G $\rightarrow$ A). Given that there are two alleles for each of the genes, the genetic test(s) may identify individuals with no mutations, individuals with a single mutation (heterozygous), or individuals with two mutations (homozygous or compound heterozygous).

Two categories of studies are available to assess analytic validity: proficiency testing exercises and method comparisons between an experimental test and a referent test. The evidence review commissioned by the EWG summarized findings from 37 method comparison studies involving FVL and 19 involving PT.3 Despite shortcomings inherent in method comparison studies, which may include investigational and clinical tests, the overall conclusions are consistent with those from proficiency testing studies (described later).

Proficiency testing programs assess laboratory performance by means of interlaboratory comparisons. The proficiency testing program sends blinded samples to multiple laboratories for testing. The results are returned to the proficiency testing provider, graded, and compared with the results obtained by other laboratories. Participants typically receive reports that describe the laboratory’s individual performance and the aggregate performance of the other participating laboratories. Proficiency testing programs document pre- and post-analytical testing errors and assay performance. They often categorize results obtained with specific assay methods and report consensus findings by participating laboratories of alleles tested and genotypes identified in each exercise. Data from proficiency testing have been suggested to be a reliable source for assessing overall laboratory performance under real-world conditions.3,27

Identification of FVL and PT mutations has been reported from proficiency testing schemes in the United States,28 the United Kingdom/Europe,28 and Australia.29 Collectively, these reports show an overall error rate of 1.0% for FVL, an analytic sensitivity of 98.8%, and an analytic specificity of 99.3%. The overall error rate for identifying PT mutations is 0.9%, with an analytic sensitivity of 98.3% and an analytic specificity of 99.6%. The reliability of test performance is high, therefore, for both FVL and PT. One of the reports38 noted that 3 of 39 laboratories were responsible for 46% of the errors, underscoring the opportunity to identify individual poor performance and encourage remedial steps.

In Appendix E of its report on genetic oversight, the Secretary’s Advisory Committee on Genetics Health and Society summarized the CAP proficiency testing data for FVL and PT during 2006.30 Overall correct response rates were between 98.9% and 99.6%. In the 2009 CAP survey, the 335 laboratories that performed FVL testing participated in three challenges.

Among the 1005 test results, two errors were recorded. Similar performance was found for the 325 laboratories testing for PT mutations. This indicates that laboratory testing performance continues to be reliable for these mutations.

Analytic validity conclusions

There is convincing evidence that analytic validity is high for both FVL and PT.

Most laboratories can test for FVL and PT with a high degree of reliability.

Clinical validity

Clinical validity is defined as a test’s ability to accurately and reliably identify or predict the disorder or phenotype of interest. As used in the evidence report and in this recommendation, clinical validity refers to the ability of FVL and PT mutation testing to predict recurrence of VTE in index cases and also to predict occurrence of VTE in asymptomatic family members of index cases who are found to carry at least one of these mutations.

Table 1 summarizes odds ratios calculated in the evidence review after pooling data from appropriate studies that examined the relationship between FVL and PT mutations and recurrent VTE or index cases. Median duration of follow-up ranged from 0.5 to 8 years. Mean annual event rates for recurrent VTE ranged from 1.8 to 7.5% (mean 3.25%).

Table 2 summarizes odds ratios calculated from the evidence review after pooling data from appropriate studies that examined the relationship between FVL and PT mutations and recurrent VTE in index cases. Median duration of follow-up was between 2.8 and 5.7 years. Annual rates for an initial VTE event ranged from 0.09 to 0.56%.

Three studies examined age-related relative risks among individuals with one or more copies of FVL mutations in comparison with family members without a FVL mutation. Table 3 summarizes the results. The first showed a considerably higher relative rate for first lifetime VTE events in the youngest age group of FVL carriers than in older age groups, when compared with family members with no FVL mutations.31 The second and

<table>
<thead>
<tr>
<th>Genotype definition</th>
<th>Included studies</th>
<th>Genotype (no. patients)</th>
<th>Pooled odds ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FVL, one copy</td>
<td>13</td>
<td>979 3751</td>
<td>1.56 (1.14–2.12)</td>
</tr>
<tr>
<td>FVL, two copies</td>
<td>8</td>
<td>49 2333</td>
<td>2.65 (1.18–5.97)</td>
</tr>
<tr>
<td>FVL, unspecified</td>
<td>3</td>
<td>68 294</td>
<td>1.56 (0.75–3.25)</td>
</tr>
<tr>
<td>FVL and PT (one copy each)</td>
<td>3</td>
<td>10 833</td>
<td>4.81 (0.50–46.0)</td>
</tr>
<tr>
<td>PT, one copy</td>
<td>10</td>
<td>281 3355</td>
<td>1.45 (0.96–2.21)</td>
</tr>
<tr>
<td>PT, two copies</td>
<td>0</td>
<td>—  —</td>
<td>—</td>
</tr>
<tr>
<td>PT, unspecified</td>
<td>4</td>
<td>86 1057</td>
<td>0.73 (0.37–1.44)</td>
</tr>
<tr>
<td>All PT combined</td>
<td>14</td>
<td>367 4412</td>
<td>1.23 (0.87–1.70)</td>
</tr>
</tbody>
</table>
Excess risk is likely to be at least as great as with heterozygosity for Factor V Leiden (FVL) and/or prothrombin (PT) in asymptomatic family members is predictive of VTE (the comparison with family members without a mutation. Adequate information rates associated with FVL is considerably increased occurrence risks associated with FVL is considerable greater than recurrence risks after an initial episode of VTE. One possible explanation, mentioned in the preceding paragraph, is that other risk factors predominate after VTE has occurred. There is no agreement about the influence of age on VTE rates in family members with an FVL mutation, when compared with family members without a mutation. Adequate evidence indicates that compound heterozygosity (for FVL and PT) in asymptomatic family members is predictive of VTE (the excess risk is likely to be at least as great as with heterozygosity for FVL, alone). Insufficient data are available to draw conclusions about the predictive power of a heterozygous PT mutation for VTE in family members of index cases. Homozygosity for PT is a rare genotype, and its association with VTE in asymptomatic family members cannot presently be determined due to lack of data. Data concerning pregnant family members are sparse.

### Clinical utility

#### Behavior/treatment patterns

A study in Washington State surveyed 112 primary care physicians who ordered FVL testing as part of their practices. Eighty-two percent indicated that they would use test results to counsel their patients about VTE recurrence risks, whereas 67% would use results to make decisions about treatment and prevention. The degree of confidence of these physicians in their ability to interpret or communicate test results was not high, and the physicians were not confident about when the test should be ordered. A second study by the group in Washington used a record review to examine the use of FVL testing in clinical practice. Uptake of testing did not follow existing recommendations, and test results were used to influence patient management in the absence of supporting evidence related to health outcomes.

#### Intervention effectiveness: Warfarin use in FVL carriers

The four studies summarized below examined recurrence rates of VTE during anticoagulation. None of these studies was designed to examine how FVL or PT testing influences patient management or whether choosing treatment based on such testing alters outcomes.

**Study 1.** Table 4 contains data from a prespecified cohort study nested within a randomized controlled trial of long-term, low-intensity warfarin therapy for the prevention of recurrent VTE in the United States. At baseline, 36.8% and 40.0% of participants in placebo and warfarin treatment groups, respectively, had experienced two or more episodes of VTE. All patients had been given 3 months of uninterrupted warfarin treatment before randomization and were followed for up to 4.5 years (mean length of follow-up: 2.1 years). Low-intensity warfarin reduced VTE recurrence by 75% among individuals with FVL or PT mutations and by 58% among those without mutations (difference not significant). Numbers of homozygotes and compound heterozygotes were not specified. Based on this prespecified subgroup analysis, the study concluded that the protective effect of warfarin did not differ based on mutation status.

**Study 2.** Table 5 summarizes data from a cohort analysis nested within a randomized controlled trial in Canada that sought to compare VTE recurrence rates during treatment with low-intensity versus conventional doses of warfarin. Before being randomized, all patients received 3 months of uninterrupted treatment with warfarin. At baseline, 51% of all participants had experienced two previous episodes of VTE, whereas 16% had experienced three and 6% four previous episodes of VTE. Follow-up was for an average of 2.3 years. Comparative recurrence rates for the two treatment regimens are presented in the table and were limited to two categories: (1) all thrombophilias (including FVL and PT mutations, as well as antiphospholipid antibodies, Factor VII/IX elevations, and others) and (2) no thrombophilias. The rate of VTE recurrence was 0.8 per 100 person years among patients with FVL mutation(s), when both levels of treatment were combined. This was not different from

---

### Table 2 Occurrence of venous thromboembolism: pooled odds ratios comparing the occurrence of an initial event in asymptomatic family members with and without Factor V Leiden (FVL) and/or prothrombin (PT) mutations

<table>
<thead>
<tr>
<th>Genotype definition</th>
<th>Included studies</th>
<th>Genotype (no. patients)</th>
<th>Pooled odds ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Present</td>
<td>Absent</td>
</tr>
<tr>
<td>FVL, one copy</td>
<td>6</td>
<td>1066</td>
<td>940</td>
</tr>
<tr>
<td>FVL, two copies</td>
<td>5</td>
<td>48</td>
<td>850</td>
</tr>
<tr>
<td>FVL, unspecified</td>
<td>6</td>
<td>1023</td>
<td>2808</td>
</tr>
<tr>
<td>FVL and PT (one copy each)</td>
<td>3</td>
<td>49</td>
<td>674</td>
</tr>
<tr>
<td>PT, one copy</td>
<td>3</td>
<td>182</td>
<td>703</td>
</tr>
<tr>
<td>PT, two copies</td>
<td>0</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>PT, unspecified</td>
<td>0</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

---

 third studies, however, found that relative rates did not differ significantly by age. Overall relative rates ranged from 2.8 to 4.2, similar to the rates shown in Table 2 for individuals with FVL mutations (either one copy or unspecified).

Among relatives with no FVL mutation, annual VTE incidence rates for the three studies were: 0.1%, 0.09%, and 0.15%, respectively.

The evidence review found low-grade evidence that homozygosity for FVL in pregnant family members is predictive of VTE. Evidence was insufficient, however, to reliably determine the predictive value of heterozygosity for FVL, PT G20210A, or the two in combination in pregnant family members.

**Clinical validity conclusions**

**Index cases (patients).** There is convincing evidence that the presence of heterozygous or homozygous FVL is associated with an increased risk of recurrent VTE in index cases (Table 1). The magnitude of this excess risk, however, is small in comparison with the baseline recurrence risk conferred by the history of idiopathic VTE alone. There is convincing evidence that one copy of a PT mutation is not predictive of VTE recurrence. The evidence is inadequate to draw conclusions about the extent of excess risk for VTE recurrence resulting from combined heterozygosity (FVL and PT), but it is likely to be at least as high as with FVL, alone.

**Relatives.** There is convincing evidence that homozygosity for FVL is associated with an increased risk for an initial episode of VTE in asymptomatic family members of index cases, and there is convincing evidence that heterozygosity for FVL in family members is also predictive of VTE (Table 2). The magnitude of increased occurrence risks associated with FVL is considerably greater than recurrence risks after an initial episode of VTE. One possible explanation, mentioned in the preceding paragraph, is that other risk factors predominate after VTE has occurred. There is no agreement about the influence of age on VTE rates in family members with an FVL mutation, when compared with family members without a mutation. Adequate evidence indicates that compound heterozygosity (for FVL and PT) in asymptomatic family members is predictive of VTE (the excess risk is likely to be at least as great as with heterozygosity for FVL, alone).
the rate among patients without FVL. Insufficient data were available to estimate a hazard ratio for PT mutations.

**Study 3.** A European randomized controlled trial examined the extent to which oral ximelagatran reduces VTE recurrence compared with placebo during an 18-month study period. Ximelagatran was a new drug with anticoagulant properties that allowed more convenient long-term management because of a lesser need for frequent laboratory monitoring. It was withdrawn from the market in 2006 because of occasional severe liver complications. Patients with one to four previous episodes of VTE were included in the randomized trial. However, the majority of participants had experienced only a single episode at baseline. All patients had received 6 months of uninterrupted warfarin before randomization, with an average length of 1.5 years follow-up. Table 6 summarizes a cohort analysis nested within that trial showing that ximelagatran treatment significantly lowered the rate of recurrence among patients with FVL and that the impact of treatment on recurrence was similar for patients with and without an FVL mutation. There were too few patients with PT mutations to obtain an accurate estimate.

**Study 4.** A prospective cohort study, also from Europe, documented rates of VTE recurrence among patients with idiopathic VTE on long-term anticoagulation with warfarin in comparison to those not on treatment. Only participants with a single previous VTE episode were included in the prospective followup. Average follow-up was 5.6 years. The study included a subset of FVL patients, but there were too few FVL patients on long-term treatment to derive a reliable estimate. Table 7 presents the data from that study, which indicate that FVL mutation carriers have a lower observed point estimate for the rate of recurrence, but the differences are not statistically significant (P = 0.184). For the study as a whole, the VTE recurrence rate was significantly lower among those on warfarin treatment than among FVL patients not receiving anticoagulation.

### Decision modeling studies

Although no direct evidence of thrombophilia testing on clinical outcomes is available, several decision modeling studies have examined potential outcomes and are summarized in the recent evidence report. Those studies provided indirect evidence that, under certain modeled scenarios, testing for FVL or PT variants and the findings of these studies should be reassessed. One study did evaluate a clinical scenario relatively consistent with the data compiled in the evidence review. In this scenario, the risk of VTE was approximately 7%, and the strategy of FVL testing followed by 3 years of warfarin treatment compared with no FVL testing and standard warfarin prophylaxis had essentially identical clinical outcomes. The authors also found that in the base case scenario (with a higher assumed VTE risk), if the risk of major bleeding was above 1.9%/year, then FVL testing may lead to poorer overall outcomes. If the VTE risk is actually lower as suggested by the recent evidence review, the threshold for major bleeding would be even lower and well within the realm of known risk of major bleeding from warfarin. Thus, in summary, informally applying

### Table 3 Age-related relative risks for first lifetime venous thromboembolism (VTE) events in family members with and without Factor V Leiden (FVL) mutations

<table>
<thead>
<tr>
<th>FVL heterozygosity (no. patients)</th>
<th>Present</th>
<th>Absent</th>
<th>Total VTE events (FVL/no FVL)</th>
<th>Overall (95% CI)</th>
<th>Relative rates</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>By age</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>15–30</td>
</tr>
<tr>
<td>268</td>
<td>203</td>
<td>32/6</td>
<td>4.2 (nr)</td>
<td></td>
<td>15</td>
</tr>
<tr>
<td>91</td>
<td>90</td>
<td>20/5</td>
<td>3.7 (1.4–10)</td>
<td></td>
<td>4.0</td>
</tr>
<tr>
<td>224</td>
<td>154</td>
<td>17/4</td>
<td>2.8 (1.1–8.6)</td>
<td></td>
<td>3.6</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>nr</td>
</tr>
</tbody>
</table>

*nr, not reported.*

### Table 4 Reduction in recurrent venous thromboembolism (VTE) by use of anticoagulation therapy, stratified by presence/absence of Factor V or prothrombin mutations

<table>
<thead>
<tr>
<th>Anticoagulation</th>
<th>Mutation status</th>
<th>No. subjects</th>
<th>VTE recurrences (per 100 person yr)</th>
<th>Hazard ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo Carrier</td>
<td>77</td>
<td>14 (8.6)</td>
<td>0.25 (0.07–0.85)</td>
<td></td>
</tr>
<tr>
<td>Placebo Noncarrier</td>
<td>176</td>
<td>23 (6.6)</td>
<td>0.42 (0.20–0.86)</td>
<td></td>
</tr>
<tr>
<td>Low-intensity warfarin Carrier</td>
<td>66</td>
<td>3 (2.2)</td>
<td>0.7 (0.2–2.6)</td>
<td></td>
</tr>
<tr>
<td>Low-intensity warfarin Noncarrier</td>
<td>189</td>
<td>11 (2.7)</td>
<td>0.42 (0.20–0.86)</td>
<td></td>
</tr>
</tbody>
</table>

*Heterozygous for either the FVL or prothrombin mutation; four of five are FVL.*

*Risk reduction not significantly different between carriers and noncarriers.*

### Table 5 Reduction in recurrent venous thromboembolism (VTE) due to anticoagulation therapy, stratified by presence/absence of Factor V or prothrombin mutations

<table>
<thead>
<tr>
<th>Anticoagulation</th>
<th>FVL mutation status</th>
<th>No. subjects</th>
<th>VTE recurrences (per 100 person yr)</th>
<th>Hazard ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Warfarin Carrier</td>
<td>171</td>
<td>3 (0.8)</td>
<td>0.7 (0.2–2.6)</td>
<td></td>
</tr>
<tr>
<td>Warfarin Noncarrier</td>
<td>475</td>
<td>11 (1.1)</td>
<td>0.7 (0.2–2.6)</td>
<td></td>
</tr>
<tr>
<td>Low vs. reg. Warfarin All thrombophilias</td>
<td>475</td>
<td>11 (1.1)</td>
<td>0.7 (0.2–2.6)</td>
<td></td>
</tr>
<tr>
<td>Low vs. reg. Warfarin No thrombophilias</td>
<td>189</td>
<td>11 (2.7)</td>
<td>0.42 (0.20–0.86)</td>
<td></td>
</tr>
</tbody>
</table>

*Includes 161 heterozygotes and 10 homozygotes.*

*Risk reduction not significantly different between carriers and noncarriers.*

---

72 © 2011 Lippincott Williams & Wilkins

---

---

---

---
able benefit/harm ratio might explain why no studies are avail-
least three times as great as a thrombotic event. This unfavor-
the length of follow-up is equal among the groups.

recurrence in carriers and noncarriers of Factor V Leiden
(FVL), stratified by treatment

<table>
<thead>
<tr>
<th>Anticoagulation</th>
<th>FVL mutation status</th>
<th>No. subjects</th>
<th>VTE recurrences (rate)</th>
<th>Relative risk (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td>Carrier</td>
<td>125&lt;sup&gt;a&lt;/sup&gt;</td>
<td>16 (13%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Noncarrier</td>
<td>406</td>
<td>41 (10%)</td>
<td>1.2 (0.7–2.1)</td>
</tr>
<tr>
<td>Ximelagatran</td>
<td>Carrier</td>
<td>111&lt;sup&gt;b&lt;/sup&gt;</td>
<td>2 (1.8%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Noncarrier</td>
<td>438</td>
<td>7 (1.6%)</td>
<td>1.1 (0.2–5.3)</td>
</tr>
</tbody>
</table>

<sup>a</sup>Publication did not report (or include sufficient data to compute) the hazard ratio—the relative risk assumes the length of follow-up is equal among the groups.
<sup>b</sup>Includes four homozygotes.
<sup>c</sup>Includes 11 homozygotes.

current estimates of risk imparted by FVL or PT variants to previous cost-effectiveness studies suggests that routine testing is not effective and not cost-effective. Formal updates of these analyses would be helpful in further clarifying these issues.

Patients who have experienced a VTE event related to a modifiable risk factor such as oral contraceptives generally are not candidates for long-term warfarin therapy. The presence of FVL homozygosity might, however, represent an indication for such extended treatment. In the absence of formal studies, evaluation of the potential risks and benefits in this patient population is challenging, given the complexity of the clinical scenario and inherent risk-benefit trade-off of warfarin therapy.

FVL and PT testing among relatives

Data summarized in the present report indicate that the risk for an initial VTE event to occur in an asymptomatic family member with one copy of an FVL mutation is approximately 3.5 times as high as among family members who do not have the mutation. If we assume that this baseline is comparable with an annual population background VTE incidence rate of approximately 10 per 10,000 (among relatives with no FVL mutation, annual VTE incidence rates for the three studies in Table 3 were 0.1%, 0.09%, and 0.15%, respectively), the rate among relatives with a single copy of FVL would be approximately 35 per 10,000. As a counterbalancing factor, anticoagulant treatment carries an annual risk for hemorrhage of at least 100 per 10,000 patient years.<sup>47</sup> Thus, the risk of a hemorrhagic event is at least three times as great as a thrombotic event. This unfavorable benefit/harm ratio might explain why no studies are avail-

able involving anticoagulation of family members with FVL. The greatest increase in risk for VTE occurs when a family member is identified with homozygous FVL. In this situation, the current data indicate that the annual risk for an initial VTE event is approximately 18 times as high as for relatives who do not have a FVL mutation, translating into a rate of approximately 180 per 10,000 per year under the assumptions mentioned earlier. The risk for an initial VTE event in these patients is thus sufficiently high to consider preemptive anticoagulation therapy, but there are no data on the outcomes of anticoagulation in such asymptomatic patients.

Although FVL homozygosity is rare (approximately 1 per 5000 in the general population), it is theoretically possible to design a selective strategy for identifying homozygous family members that begins with FVL testing in index cases of VTE. As an example, a hypothetical cohort of 1000 non-Hispanic white patients with VTE might be genotyped for FVL, with 200 identified as having at least one FVL mutation. The spouses of those 200 with FVL mutations would then be genotyped, eight of whom would also be heterozygous. Assuming 16 offspring for those eight couples (two per family), four would be homozygous. This scenario assumes 100% participation. The preceding example, although subject to modification and refinement, offers a reasonable expectation of new homozygous individuals identified among family members, under optimal conditions. No formal studies assessing preemptive anticoagulation in family members were identified.

Summary

The present recommendation statement is based on an evidence report that focused on a prespecified clinical scenario involving adults with a history of idiopathic VTE and their asymptomatic adult family members. The evidence report did not extend to patients with other known risk factors for thrombosis, such as contraceptive use.

Testing for patients

For index cases with VTE, clinical utility depends on the extent to which identification of a FVL or PT mutation alters management to incrementally prevent recurrence of VTE, thereby leading to health-related outcomes that are improved over current practice. There is evidence that longer term anticoagulation benefits patients both with and without FVL or PT mutations. Longer term warfarin administration assumes that there are no contraindications and that there is access to, and compliance with, accurate therapeutic monitoring. There is evidence from one chart review survey that management may be altered by knowledge that one of these mutations is present. However, uptake of testing did not follow existing recommendations, and test results were used to influence patient management in the absence of supporting evidence related to health outcomes.<sup>40</sup>

The net benefit of warfarin therapy includes consideration of both benefits (prevention of VTE) and harms (bleeding risk). The most immediate potential harm with instituting prolonged anticoagulation arises from anticoagulant-induced hemorrhage. The risk of major bleeding due to anticoagulant treatment is at least 1–3% per year, of which one in five cases is fatal.<sup>47,48</sup> The risk of bleeding complications rises significantly with age and the achieved International Normalized Ratio.<sup>49</sup> A net benefit would be achieved if enough VTE recurrences could be prevented that risk of an occasional hemorrhagic event would be acceptable. The data indicate that this balance of benefits and harms should be applied to post-VTE patients, regardless of mutation status, and that a favorable balance may be achieved.

Table 6 Relative risk of venous thromboembolism (VTE) recurrence in carriers and noncarriers of Factor V Leiden (FVL), stratified by treatment

<table>
<thead>
<tr>
<th>Anticoagulation</th>
<th>FVL mutation status</th>
<th>No. subjects</th>
<th>VTE recurrences (rate)</th>
<th>Hazard ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Noncarrier</td>
<td>13</td>
<td>0 (0.0)</td>
<td></td>
<td>&lt;1.0</td>
</tr>
<tr>
<td>Noncarrier</td>
<td>111</td>
<td>7 (1.2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No long-term</td>
<td>Carrier</td>
<td>79</td>
<td>13 (3.5)</td>
<td></td>
</tr>
<tr>
<td>Noncarrier</td>
<td>101</td>
<td>16 (5.8)</td>
<td>1.7 (0.8–3.5)</td>
<td></td>
</tr>
<tr>
<td>Long-term</td>
<td>Carrier</td>
<td>13</td>
<td>0 (0.0)</td>
<td></td>
</tr>
<tr>
<td>Noncarrier</td>
<td>111</td>
<td>7 (1.2)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 7 Relative risk of venous thromboembolism (VTE) recurrence in carriers and noncarriers of Factor V Leiden (FVL), stratified by treatment

<table>
<thead>
<tr>
<th>Anticoagulation</th>
<th>FVL mutation status</th>
<th>No. subjects</th>
<th>VTE recurrences (per 100 person yr)</th>
<th>Hazard ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td>Carrier</td>
<td>125&lt;sup&gt;a&lt;/sup&gt;</td>
<td>16 (13%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Noncarrier</td>
<td>406</td>
<td>41 (10%)</td>
<td>1.2 (0.7–2.1)</td>
</tr>
<tr>
<td>Ximelagatran</td>
<td>Carrier</td>
<td>111&lt;sup&gt;b&lt;/sup&gt;</td>
<td>2 (1.8%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Noncarrier</td>
<td>438</td>
<td>7 (1.6%)</td>
<td>1.1 (0.2–5.3)</td>
</tr>
</tbody>
</table>

<sup>a</sup>Publication did not report (or include sufficient data to compute) the hazard ratio—the relative risk assumes the length of follow-up is equal among the groups.
<sup>b</sup>Includes four homozygotes.
<sup>c</sup>Includes 11 homozygotes.
through longer term anticoagulation. Special considerations, such as might occur when VTE is associated with oral contraceptives or hormone replacement therapy, are not considered here.

Testing of relatives

There are no published comparative trials involving primary chronic anticoagulant administration to asymptomatic family members of index cases with one or more of these mutations. Clinical utility again depends on the extent to which management changes when a mutation is identified and, most importantly, how effectively such management leads to avoidance of VTE. If any strategy to achieve this improvement would prominently include use of anticoagulation agents, such as warfarin, then the most immediate potential harm would be a hemorrhagic event. The balance between benefits and harms will differ from that in index cases, however, because the risk for an initial VTE event to occur among heterozygous family members is much lower than that for a recurrent event in an index case.

Clinical utility conclusions

- There is no evidence that knowledge of FVL/PT mutation status in patients with VTE affects anticoagulation treatment to avoid recurrence.
- There is convincing evidence that anticoagulation beyond 3 months reduces recurrence of VTE, regardless of mutation status.
- There is no evidence that knowledge of FVL/PT mutation status among asymptomatic family members of patients with VTE leads to anticoagulation aimed at avoiding initial episodes of VTE.

Clinical trials

A search was done on the website ClinicalTrials.gov, using the terms “factor V Leiden,” “R506Q,” “G1691A,” and “G20210A” (October 2, 2009). No clinical validity or clinical utility-related implications were identified that would be expected to affect future recommendations relating to the current specific clinical scenario. Regarding analytic validity, one ongoing external validation study was found comparing performance of FVL and PT testing using VeraCode Genotyping on a BeadXpress System versus bidirectional sequencing (http://clinicaltrials.gov/ct2/show/NCT00959504?term=factor+v+leiden&rank=4). No relevant additional results were obtained from searches of the WHO International Clinical Trials Registry Platform (http://www.who.int/ictrp/en/), using the same search terms on the same date.

Contextual issues important to the recommendation

Cost-effectiveness

- Cost-effectiveness modeling studies in this area require updating with current VTE risk estimates but are suggestive that routine FVL/PT testing is not cost-effective.

Research gaps

The research literature is insufficient in many respects, and the EWG recommends further studies that could address important gaps in knowledge. Among these gaps, the EWG found the following:

- Few data on how either homozygosity for FVL/PT or compound heterozygosity might lead to individualized management and thereby avoid either occurrence or recurrence of VTE.
- No information about how knowledge of FVL/PT mutation status might affect behavior (i.e., motivation) for adherence to anticoagulation treatment after a VTE episode.
- No information about other related issues, such as relief of anxiety that might result from identification of FVL status.
- No formal risk-benefit or cost-effectiveness analyses using current estimates of VTE risk imparted by FVL/PT variants.

It is speculated that absence of data on anticoagulation strategies for asymptomatic family members who are heterozygous for FVL might be explained by an unfavorable risk/benefit balance because of low absolute risk for VTE. This is not considered a gap in knowledge.

Recommendations of other groups

Several guidelines and recommendations pertinent to our present clinical scenario for FVL/PT mutation testing have been published. Because EGAPP aims to address clinical and public health practice issues within the US health care system, we have limited discussion in this section to US guidelines and recommendations.

American College of Medical Genetics Consensus Statement on FVL mutation testing includes the following:

- “[…] There is growing consensus that FVL testing should be performed, following the same general recommendations as for any thrombophilia. Random screening of the general population for factor V Leiden is not recommended.”
- “Patients testing positive for factor V Leiden or APC resistance should be considered for molecular genetic testing for […] the prothrombin 20210A variant…”

CAP consensus recommendations include the following:

- “Tests for factor V Leiden […], and prothrombin G20210A mutation are appropriate in patients with VTE (particularly for idiopathic VTE), for younger patients, and/or for patients with a family history of thrombosis, Level 2, with a small number of level 1 references cited”
- “Heterozygous or homozygous FVL carriers with a first lifetime deep vein thrombosis or pulmonary embolism should be treated in standard fashion”

American College of Chest Physicians evidence-based clinical practice guidelines, antithrombotic therapy for venous thromboembolic disease, acknowledge that:

- “The presence of hereditary thrombophilia has not been used as a major factor to guide duration of anticoagulation for VTE in these guidelines because evidence from prospective studies suggests that these factors are not major determinants of the risk of recurrence.”

Also state that:

- “For patients with DVT secondary to a transient (reversible) risk factor, we recommend treatment with a VKA [vitamin K antagonist] for 3 months over treatment for shorter periods (Grade 1A).”
- “For patients with unprovoked DVT, we recommend treatment with a VKA for at least 3 months (Grade 1A). We recommend that after 3 months of anticoagulant therapy,
all patients with unprovoked DVT should be evaluated for the risk-to-benefit ratio of long-term therapy (Grade 1C). For patients with a first unprovoked VTE that is a proximal DVT, and in whom risk factors for bleeding are absent and for whom good anticoagulant monitoring is achievable, we recommend long-term treatment (Grade 1A). Values and preferences: This recommendation attaches a relatively high value to prevention of recurrent VTE and a lower value to the burden of long-term anticoagulant therapy.

Although recommendations and guidelines from international groups are not covered in the present recommendation statement, interested readers may find comparisons of our findings with international guidelines such as these (British Committee on Standards in Haematology53; European Genetics Foundation, Cardiovascular Disease Educational and Research Trust, International Union of Angiology, Mediterranean League on Thrombophilia54; French Group on Hemostasis and Thrombosis, and French Society of Vascular Medicine55) to be both interesting and illuminating.

REFERENCES

30. Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity...
warfarin therapy for the prevention of recurrent venous thromboembolism. 
recurrent venous thromboembolism while on warfarin: results from a ran-
thromboembolism or bleeding in relation to thrombophilic risk factors in 
patients receiving ximelagatran or placebo for long-term secondary preven-
44. Schulman S, Wåhlander K, Lundström T, Clason SB, Eriksson H, THRIVE 
III Investigators. Secondary prevention of venous thromboembolism with 
the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003;349: 
1713–1721.
45. Vossen CY, Walker ID, Svensson P, et al. Recurrence rate after a first 
venous thrombosis in patients with familial thrombophilia. Arterio-
46. Eckman MH, Singh SK, Erban JK, Kao G. Testing for Factor V Leiden in 
patients with pulmonary or venous thromboembolism: a cost-effectiveness 
anticoagulant treatment: an inception-cohort, prospective collaborative study 
(ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. 
48. van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briët E. Bleeding 
complications in oral anticoagulant therapy. An analysis of risk factors. Arch 
49. Hirsh J, Lee AY. How we diagnose and treat deep vein thrombosis. Blood 
50. Grody WW, Griffin JH, Taylor AK, Korf BR, Heit JA, ACMG Factor V. 
Leiden Working Group. American College of Medical Genetics consensus 
51. Van Cott EM, Laposata M, Prins MH. Laboratory evaluation of hyperco-
agulability with venous or arterial thrombosis. Arch Pathol Lab Med 2002; 
126:1281–1295.
52. Press RD, Bauer KA, Kujovich JL, Heit JA. Clinical utility of Factor V 
leiden (R506Q) testing for the diagnosis and management of thromboem-
54. Nicolaides AN, Breddin HK, Carpenter P, et al. Thrombophilia and venous 
thromboembolism. International consensus statement. Guidelines according 
testing for thrombophilia in venous thromboembolic disease: a French 

EGAPP Working Group

Genetics in Medicine • Volume 13, Number 1, January 2011

© 2011 Lippincott Williams & Wilkins

Copyright © American College of Medical Genetics. Unauthorized reproduction of this article is prohibited.